8-K: Enhabit Home Health & Hospice Showcases Strong Q1 2025 Performance and Strategic Momentum at Goldman Sachs Conference

Enhabit Home Health & Hospice presented its Q1 2025 highlights, strategic priorities, and strong hospice growth momentum at the Goldman Sachs 46th Annual Global Healthcare Conference.

Summary

• Enhabit reported strong Q1 2025 highlights, including sequential growth in home health census and 14 consecutive months of sequential average daily census (ADC) growth in hospice.
• The company successfully reduced its net debt to Adjusted EBITDA leverage ratio to 4.4x in Q1 2025, a 0.9x reduction since Q1 2024, achieving its credit agreement target one quarter earlier than required, which will lift various credit agreement restrictions.
• Hospice volume (ADC) reached 3,809 in Q1 2025, representing a 12.3% year-over-year increase and 2.1% sequential growth.
• Home Health total admissions were 57,222 in Q1 2025, up 8.1% year-over-year and 0.7% sequentially.
• Home Health volume (Total ADC) was 41,236 in Q1 2025, a 3.7% increase year-over-year, despite a slight 0.5% sequential decline.
• Home Health Adjusted EBITDA Margin improved to 20.3% in Q1 2025, up 1.4% from Q4 2024.
• The company's 2025 priorities include growing home health and hospice census, optimizing payer mix, opening and optimizing de novo locations, managing G&A expenses, and improving unit economics (cost/revenue per patient day).
• Enhabit is shifting its reporting view for segment performance metrics starting year-end 2024, focusing on one volume metric (ADC) and consistent unit revenue and cost metrics (per patient day).
• The company operates in large and growing addressable markets, with projected Medicare skilled home health expenditures of ~$41 billion and Medicare Hospice expenditures of ~$32 billion by 2028.

Sentiment

Score: 8

Explanation: The document conveys a highly positive sentiment, emphasizing strong operational performance, significant de-leveraging ahead of schedule, and a clear strategic path within a favorable industry environment. The early achievement of financial covenants is a particularly strong positive indicator.

Positives

• Hospice segment demonstrated strong growth momentum with 14 consecutive months of sequential Average Daily Census (ADC) growth, reaching 3,809 in Q1 2025, up 12.3% year-over-year.
• The company significantly reduced its Net Debt to Adjusted EBITDA Leverage Ratio to 4.4x in Q1 2025, a 0.9x reduction from Q1 2024, achieving its target one quarter earlier than credit agreement requirements, which will lead to lifted restrictions.
• Home Health total admissions increased by 8.1% year-over-year to 57,222 in Q1 2025.
• Home Health Adjusted EBITDA Margin improved to 20.3% in Q1 2025, showing a 1.4% sequential increase.
• The rate of decline in Home Health Medicare Fee-for-Service (FFS) volumes is slowing, with Medicare revenue as a % of segment revenue at 55.7% in Q1 2025.
• Strategic focus on growing patient census, optimizing payer mix, and improving unit economics is clearly defined.
• The company benefits from attractive industry tailwinds, including an aging population, a strong preference for home-based care, and the cost efficiency of home health and hospice services (10x lower cost than other care settings).

Negatives

• Home Health Volume (Total ADC) experienced a slight sequential decline of 0.5% from Q4 2024 to Q1 2025, though it was up year-over-year.
• Medicare Fee-for-Service (FFS) volumes for Home Health are still declining, despite a slowing rate of decline.

Risks

• Ability to execute on strategic plans.
• Regulatory and other developments impacting the markets for services.
• Changes in reimbursement rates.
• General economic conditions.
• Changes in the episodic versus non-episodic mix of payers, the case mix of patients, and payment methodologies.
• Ability to attract and retain key management personnel and healthcare professionals.
• Potential disruptions or breaches of the company's or its vendors', payers', and other contract counterparties' information systems.
• The outcome of litigation.
• Quality performance and ratings.
• Ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures.
• Ability to successfully integrate technology in operations.
• Ability to control costs, particularly labor and employee benefit costs.

Future Outlook

Enhabit anticipates continued growth in patient census, stabilization of unit revenue through a healthy payer mix, and a focus on strategic levers including growing volume, slowing the decline of Medicare fee-for-service, and improving mix shift to payer innovation. The company expects long-term growth to be supported by favorable demographic trends, such as an aging population, and the inherent cost-effectiveness of its home health and hospice services.

Management Comments

• "The Company will revert to the pricing grid and various credit agreement restrictions will be lifted" (following the early achievement of leverage ratio targets).
• "Growing patient census is a primary driver of financial results in our segments."
• "Focus on a healthy payer mix should stabilize unit revenue."
• "Clear Translation to Margin Performance: Grow Volume = ADC, Stabilize Unit Rev = revenue per patient day, Lower Unit Cost = cost of services per patient day."

Industry Context

The document highlights significant industry tailwinds for Enhabit, including a rapidly aging population, with 75% of those aged 50 and over expressing a desire to stay in their residence as they age. Home health and hospice care are presented as highly cost-efficient alternatives, being 10x lower in cost than other care settings. Specifically, the average Medicare cost per day for home health is $63, compared to $186 for hospice and $556 for skilled nursing facilities. The addressable markets are substantial and growing, with projected Medicare skilled home health expenditures of approximately $41 billion and Medicare Hospice expenditures of approximately $32 billion by 2028, indicating robust demand for Enhabit's services.

Comparison to Industry Standards

• Home health care is presented as 10x lower in cost than other care settings, positioning Enhabit's services as a highly cost-efficient option within the broader healthcare landscape.
• Specific average Medicare cost per day comparisons are provided: Skilled Nursing Facilities (SNF) at $556, Hospice at $186, and Home Health at $63, demonstrating the significant cost advantage of home-based care.
• The document references data from MedPAC reports (March 2023, December 2024) and an AARP 2024 Survey, indicating that the company's analysis of market trends and cost efficiencies is aligned with recognized industry benchmarks and surveys.
• The company's patient demographics (average age of home health patients 76, hospice patients 83) align with the broader trend of an aging population, which is a key driver for the home healthcare industry.

Corporate Governance

Legal Proceedings

• The outcome of litigation is listed as a risk factor that could cause actual events or results to differ materially from forward-looking statements, but no specific legal proceedings are detailed.

Stakeholder Impact

• Shareholders/Investors: Positive impact due to improved financial health (reduced leverage ahead of schedule), strong operational growth in key segments (hospice), and clear strategic direction, potentially leading to increased investor confidence and share price appreciation.
• Employees/Healthcare Professionals: Positive impact through a focus on 'Engagement,' 'Retention,' and 'Leadership development,' indicating investment in human capital.
• Patients/Families: Positive impact from the company's focus on 'Patient and family experience,' 'quality performance and ratings,' and efforts to reduce 'Home health hospital readmission rates' and improve 'Hospice visits in the last days of life,' suggesting enhanced care quality.
• Creditors: Positive impact due to the company's early achievement of leverage ratio targets, demonstrating strong financial discipline and reduced credit risk.
• Referral Sources: The strategy to be a 'full-service provider to referral sources' suggests strengthening relationships and improving service offerings to partners.

Next Steps

• Continue de-leveraging the balance sheet.
• Open de novo locations in strategic markets.
• Optimize de novo locations opened in 2023 and 2024.
• Implement a new view of segment performance metrics reporting beginning with the year-end 2024 earnings release.
• Focus on growing volume, stabilizing unit revenue, and lowering unit costs to improve gross and EBITDA margins.

Key Dates

Recommendation

Keywords

Enhabit, Home Health, Hospice, Healthcare, SEC Filing, 8-K, Investor Presentation, Goldman Sachs, Q1 2025, Financial Results, Adjusted EBITDA, Leverage Ratio, Patient Census, Average Daily Census, Medicare, Payer Mix, Strategic Plan, Corporate Governance, Risk Management